A. Calvo

发表

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

J. Tabernero, G. Prager, A. Stein, 2021, ESMO open.

Error Detection and Cost Savings With an Image-Based Workflow Management System Connected to a Computerized Prescription Order Entry Program for Antineoplastic Compounding

C. Rodriguez-Gonzalez, V. Escudero-Vilaplana, I. Iglesias-Peinado, 2019, Journal of patient safety.

Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles

S. Servitja, Ana Milena, A. Barnadas, 2012, Clinical and Translational Oncology.

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

I. Melero, M. Rodriguez-Ruiz, P. López-Casas, 2020, Science Translational Medicine.

Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.

Miguel Martín, A. M. Muñoz Martín, E. de Ramón, 2018, Anticancer research.

Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

V. Arrazubi, P. Jiménez-Fonseca, J. Gallego, 2022, Journal of Cancer Research and Clinical Oncology.

Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.

F. Hodi, Y. Bang, H. Joensuu, 2018 .

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

P. Ascierto, R. Plummer, E. Felip, 2022, Cancer Chemotherapy and Pharmacology.

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.

J. Tabernero, N. Amellal, A. Cervantes, 2019, European journal of cancer.

CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20).

S. Dolfi, H. Vezina, I. Lugowska, 2021 .

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach

M. Sanjurjo-Sáez, L. López-Fernández, F. Thomas, 2021, Journal of personalized medicine.

Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.

Niladri Roy Chowdhury, E. Kwak, D. Tan, 2018 .

3:36 PM Abstract No. 375 Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors

S. Raman, E. Chan, A. Prat, 2018 .

Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

V. Arrazubi, P. Jiménez-Fonseca, J. Gallego, 2022, Journal of Cancer Research and Clinical Oncology.

Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors.

J. Hecht, A. Prat, J. Chesney, 2018 .

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

A. Carrato, E. Polo, E. Grande, 2019, BMC Cancer.

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

O. Mirallas, V. Arrazubi, P. Jiménez-Fonseca, 2023, Therapeutic advances in medical oncology.

Prognostic and predictive factors in metastasic colorectal cancer.

Miguel Martín, A. Rupérez, I. Gallego, 2018 .